ZILBEA

This brand name is authorized in Austria, Estonia, Lithuania

Active ingredients

The drug ZILBEA contains one active pharmaceutical ingredient (API):

1 Agomelatine
UNII A17BS39YWR - AGOMELATINE CITRIC ACID

Agomelatine is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist. In humans, agomelatine has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset.

Read about Agomelatine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
N06AX22 Agomelatine N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AX Other antidepressants
Discover more medicines within N06AX22

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1738469, 1738470
Country: LT Valstybinฤ— vaistลณ kontrolฤ—s tarnyba Identifier(s): 1092425, 1092426

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈